Mora-Lujan J, Montero A, Formiga F, Rubio-Rivas M
Medicina (Kaunas). 2025; 61(2).
PMID: 40005350
PMC: 11857332.
DOI: 10.3390/medicina61020233.
Daenen K, Boyd A, Huijben J, Stoof S, Bos L, Gommers D
J Inflamm Res. 2025; 18:2395-2408.
PMID: 39991661
PMC: 11846612.
DOI: 10.2147/JIR.S502188.
Umar A, Umer M, Ali H, Zeeshan H, Ahsan B
Cureus. 2025; 17(1):e77036.
PMID: 39917128
PMC: 11798887.
DOI: 10.7759/cureus.77036.
Alberti M, Marcucci A, Biondi F, Chiusolo S, Masini G, Faggioni L
J Cardiovasc Echogr. 2025; 34(4):160-169.
PMID: 39895893
PMC: 11784726.
DOI: 10.4103/jcecho.jcecho_59_24.
Hernandez-Blanco C, Al-Akioui-Sanz K, Herrera L, Aguirre-Portoles C, Lozano-Ojalvo D, Perez-Rodriguez L
iScience. 2025; 28(2):111698.
PMID: 39877904
PMC: 11772958.
DOI: 10.1016/j.isci.2024.111698.
Nonlinear association between admission oxygen partial pressure and in-hospital and one-year all-cause mortality in patients with coronavirus disease pneumonia: A retrospective cohort study.
Zhou R, Pan D
Sci Prog. 2024; 107(4):368504241310737.
PMID: 39726217
PMC: 11686722.
DOI: 10.1177/00368504241310737.
Perspectives on Microbiome Therapeutics in Infectious Diseases: A Comprehensive Approach Beyond Immunology and Microbiology.
Seo H, Kim S, Beck S, Song H
Cells. 2024; 13(23).
PMID: 39682751
PMC: 11640688.
DOI: 10.3390/cells13232003.
Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies.
Di X, Li Y, Wei J, Li T, Liao B
Adv Sci (Weinh). 2024; 12(3):e2410416.
PMID: 39665319
PMC: 11744640.
DOI: 10.1002/advs.202410416.
Biological and computational assessments of thiazole derivative-reinforced bile salt enriched nano carriers: a new gate in targeting SARS-CoV-2 spike protein.
Zakaria M, Elmaaty A, El-Shesheny R, Alnajjar R, Kutkat O, Ben Moussa S
RSC Adv. 2024; 14(52):38778-38795.
PMID: 39654925
PMC: 11627215.
DOI: 10.1039/d4ra07316a.
Integrated Analysis of Remdesivir and Paxlovid in COVID-19 Patients: A Personalized Approach to High-Risk Individuals for Severe Evolution.
Fitero A, Negrut N, Popa A, John H, Ferician A, Manole F
J Clin Med. 2024; 13(22).
PMID: 39597814
PMC: 11594474.
DOI: 10.3390/jcm13226670.
Human Blood Non-Classical/Classical Monocyte Cells Are Heterogeneously Presented in Severe COVID-19 and Correlate with Disease Activity.
Zhou D, Shen Y, Jing S, Qiu D, Wang Y, Qu Q
J Innate Immun. 2024; 17(1):1-9.
PMID: 39586291
PMC: 11666265.
DOI: 10.1159/000542652.
Impact of extracorporeal hemadsorption on mortality in critically ill COVID-19 patients in the intensive care unit.
Cakin O, Yuce Aktepe M, Harmandar O, Deveci K, Esra Yildirim O, Kurtoglu E
Int J Artif Organs. 2024; 47(10):736-742.
PMID: 39268922
PMC: 11512486.
DOI: 10.1177/03913988241269527.
A comprehensive IDA and SWATH-DIA Lipidomics and Metabolomics dataset: SARS-CoV-2 case control study.
Tahir A, Draxler A, Stelzer T, Blaschke A, Laky B, Szell M
Sci Data. 2024; 11(1):998.
PMID: 39266559
PMC: 11393081.
DOI: 10.1038/s41597-024-03822-y.
Effect of methylprednisolone in reducing severe COVID-19 and mortality in high-risk patients: A retrospective study.
Xiao Y, Wang J, Yang K, Jiang M, Luo J, Chen K
SAGE Open Med. 2024; 12:20503121241276683.
PMID: 39257516
PMC: 11384515.
DOI: 10.1177/20503121241276683.
Genetic variants regulating the immune response improve the prediction of COVID-19 severity provided by clinical variables.
Delgado-Wicke P, Fernandez de Cordoba-Onate S, Roy-Vallejo E, Alegria-Carrasco E, Rodriguez-Serrano D, Lamana A
Sci Rep. 2024; 14(1):20728.
PMID: 39237611
PMC: 11377536.
DOI: 10.1038/s41598-024-71476-2.
A High-Dose Corticosteroid Treatment Increases Coronavirus Disease of 2019 Mortality in Intensive Care Units.
Demir I, Yilmaz I, Yilmaz H, Ozkaratas H, Calik S
Turk J Pharm Sci. 2024; 21(4):297-302.
PMID: 39224081
PMC: 11589091.
DOI: 10.4274/tjps.galenos.2023.92645.
A Retrospective Study: Evaluating the Impact of the COVID-19 Pandemic on Inflammatory Markers in Hospitalized Patients.
Elnagi E, Al-Maqati T, Maawadh R, AlBahrani S, Al Khalaf F, Alzahrani F
Infect Dis Rep. 2024; 16(4):735-749.
PMID: 39195007
PMC: 11353753.
DOI: 10.3390/idr16040056.
Post-COVID Interstitial Lung Disease: How do We Deal with This New Entity?.
Yuksel A, Karadogan D, Hursoy N, Telatar T, Kose Kabil N, Marim F
Balkan Med J. 2024; 41(5):377-386.
PMID: 39192585
PMC: 11588920.
DOI: 10.4274/balkanmedj.galenos.2024.2024-3-82.
Antimalarial Drugs at the Intersection of SARS-CoV-2 and Rheumatic Diseases: What Are the Potential Opportunities?.
Abisheva S, Rutskaya-Moroshan K, Nuranova G, Batyrkhan T, Abisheva A
Medicina (Kaunas). 2024; 60(7).
PMID: 39064600
PMC: 11279047.
DOI: 10.3390/medicina60071171.
Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trial.
Porter J, Inshaw J, Solis V, Denneny E, Evans R, Temkin M
Elife. 2024; 12.
PMID: 39009040
PMC: 11251720.
DOI: 10.7554/eLife.87030.
